


Desethyl chloroquine diphosphate

Cat. No.:	HY-135811A
CAS No.:	247912-76-1
Molecular Formula:	C ₁₆ H ₂₈ ClN ₃ O ₈ P ₂
Molecular Weight:	487.81
Target:	Parasite; Toll-like Receptor (TLR); Autophagy
Pathway:	Anti-infection; Immunology/Inflammation; Autophagy
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 20 mg/mL (41.00 mM; ultrasonic and warming and heat to 80°C)
DMSO : 2.63 mg/mL (5.39 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.0500 mL	10.2499 mL	20.4998 mL
	5 mM		0.4100 mL	2.0500 mL	4.1000 mL
	10 mM		0.2050 mL	1.0250 mL	2.0500 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 50 mg/mL (102.50 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Desethyl chloroquine diphosphate is a major desethyl metabolite of Chloroquine. Chloroquine diphosphate is an inhibitor of autophagy and toll-like receptors (TLRs). Desethyl chloroquine diphosphate possesses antiplasmodic activity^{[1][2]}.

IC₅₀ & Target

Plasmodium TLRs

In Vivo

Intraperitoneal injections of Chloroquine are administered to wild-type and Huntington's disease (Q175/Q175) mice. LC-MS/MS is used to compare the levels Chloroquine and its metabolites in blood, brain and muscle tissue. Concentrations of

Chloroquine are lower (5-15M), but more stable in brain tissue compared to blood or muscle between 4 and 24 hours after the last dose. Levels of the active Chloroquine metabolite Desethyl chloroquine decreased in muscle and blood over the 24 hour post-injection period, while brain Desethyl chloroquine levels are lower and rose slightly over the same time frame^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2021 Jan 7;12(1):42.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Ajayi FO, et al. Comparison of the partitioning in vitro of chloroquine and its desethyl metabolites between the erythrocytes and plasma of healthy subjects and those with falciparum malaria. Afr J Med Med Sci. 1989 Jun;18(2):95-100.
- [2]. Vodicka P, et al. Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice. J Huntingtons Dis. 2014;3(2):159-74.
- [3]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA